PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
P/B ratio for PROCEPT BioRobotics Corporation (PRCT)
P/B ratio as of 2023: 7.05
According to PROCEPT BioRobotics Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.05. At the end of 2022 the company had a P/B ratio of 9.36.
P/B ratio history for PROCEPT BioRobotics Corporation from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 7.05 |
| 2022 | 9.36 |
| 2021 | 4.09 |
| 2020 | -9.92 |
| 2019 | -12.61 |